- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05575037
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease (MARINER)
February 27, 2024 updated by: Tanya Laidlaw, MD, Brigham and Women's Hospital
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease: MARINER
The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Aspirin-Exacerbated Respiratory Disease (AERD).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The protocol involves an 8-week trial of dupilumab in patients with AERD.
Participants will have 4 total doses of dupilumab administered, with each dose administered every 2 weeks.
There will be full clinical assessments and biospecimen collections at Baseline (Visit 1), Week 2 (Visit 2), and Week 8 (Visit 3).
Study Type
Interventional
Enrollment (Estimated)
33
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tanya M Laidlaw, MD
- Phone Number: 617-525-1034
- Email: tlaidlaw@bwh.harvard.edu
Study Contact Backup
- Name: Tessa Ryan
- Phone Number: 617-525-3824
- Email: tryan6@bwh.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Brigham and Women's Hospital
-
Contact:
- Laura Bailey, BA
- Phone Number: 857-307-1166
- Email: lbailey0@bwh.harvard.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
History of AERD, defined as meeting the diagnostic triad with:
- History of physician-diagnosed asthma and
- History of physician-diagnosed nasal polyposis and
- History of pathognomonic reactions to aspirin or other nonselective COX inhibitors.
- Visible nasal polyps bilaterally on otoscope physical exam at the time of screening.
- Evidence of sense of smell impairment, with a University of Pennsylvania Smell Identification Test (UPSIT) score of <34.
- Stable asthma (no glucocorticoid burst for at least 4 weeks prior to Visit 1, and no hospitalizations or ER visits for asthma for at least the prior 3 months).
- Consistent (daily) use of an intranasal steroid for at least 4 weeks prior to Screening.
- No current smoking (not more than one instance of smoking in the last 3 months).
- For females: Practicing FDA-approved methods of birth control for the duration of the study. Female participants of childbearing potential must have a negative pregnancy test upon study entry.
Key Exclusion Criteria:
- Use of investigational drugs within 12 weeks of Screening.
- Use of any biologic agent within 4 months prior to Screening.
- Use of systemic (enteral or injected) glucocorticoids within 4 weeks prior to Screening.
- History of any sinonasal surgery within 4 months prior to Screening
- Current use of zileuton
- Current use of high-dose aspirin therapy (no more than 325 mg aspirin per day will be allowed)
- Pregnant, nursing, or planning to become pregnant
Note: Other inclusion and exclusion criteria apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dupilumab
Subjects will receive dupilumab (300mg every-other-week for 8 weeks).
|
8-week trial of dupilumab (an anti-IL-4a) in patients with AERD.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nasal fluid levels of LTE4
Time Frame: At Week 8 (Visit 3)
|
The nasal fluid levels of LTE4 will be measured at week 8 and will serve as a surrogate biomarker of respiratory mast cell activation or burden.
|
At Week 8 (Visit 3)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nasal fluid levels of albumin
Time Frame: At Week 8 (Visit 3)
|
The nasal fluid levels of albumin will be measured at week 8 and serve as a surrogate biomarker of nasal epithelial cell integrity.
|
At Week 8 (Visit 3)
|
Sense of smell - University of Pennsylvania Smell Identification Test (UPSIT)
Time Frame: At Week 8 (Visit 3)
|
Patients' sense of smell will be assessed at week 8 using the UPSIT.
|
At Week 8 (Visit 3)
|
Rhinoscopic Total Polyp Score (TPS)
Time Frame: At Week 8 (Visit 3)
|
The extent of patients' nasal polyps will be assessed at week 8 using a TPS.
|
At Week 8 (Visit 3)
|
Peak Nasal Inspiratory Flow (PNIF)
Time Frame: At Week 8 (Visit 3)
|
Patients' nasal congestion will be assessed at week 8 by a PNIF.
|
At Week 8 (Visit 3)
|
Quality of life - 22-Item Sino-Nasal Outcome Test (SNOT-22)
Time Frame: At Week 8 (Visit 3)
|
Quality of life will be assessed at week 8 with a SNOT-22.
|
At Week 8 (Visit 3)
|
Lung function - Forced Expiratory Volume 1 (FEV1)
Time Frame: At Week 8 (Visit 3)
|
Patients' lung function will be assessed at week 8 with an FEV1.
|
At Week 8 (Visit 3)
|
Asthma control - Asthma Control Questionnaire-6 (ACQ-6)
Time Frame: At Week 8 (Visit 3)
|
Asthma control will be measured at week 8 with an ACQ-6.
|
At Week 8 (Visit 3)
|
Number of treatment-related adverse events (AEs) and serious adverse events (SAEs) leading to study drug discontinuation
Time Frame: At Week 8 (Visit 3)
|
Safety will be measured by the number of treatment-related AEs and SAEs leading to dupilumab discontinuation.
|
At Week 8 (Visit 3)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in sense of smell - University of Pennsylvania Smell Identification Test (UPSIT)
Time Frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in UPSIT.
|
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change in Rhinoscopic Total Polyp Score (TPS)
Time Frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in TPS.
|
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change in Peak Nasal Inspiratory Flow (PNIF)
Time Frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in PNIF.
|
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change in 22-Item Sino-Nasal Outcome Test (SNOT-22)
Time Frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in SNOT-22.
|
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change in lung function - Forced Expiratory Volume 1 (FEV1)
Time Frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in FEV1.
|
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change in Asthma control - Asthma Control Questionnaire-6 (ACQ-6)
Time Frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in ACQ-6.
|
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change in Nasal fluid levels of eicosanoids
Time Frame: weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid eicosanoid levels.
|
weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change in Nasal fluid levels of albumin
Time Frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid albumin levels.
|
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change in urinary levels of eicosanoids
Time Frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in urinary eicosanoid levels.
|
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change in serum tryptase
Time Frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in serum tryptase levels.
|
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change in IgE levels
Time Frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid and plasma levels of IgE.
|
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change in eosinophilic cationic protein (ECP)
Time Frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid levels of ECP.
|
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Tanya M Laidlaw, MD, Brigham and Women's Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2023
Primary Completion (Estimated)
April 30, 2026
Study Completion (Estimated)
April 30, 2026
Study Registration Dates
First Submitted
October 7, 2022
First Submitted That Met QC Criteria
October 7, 2022
First Posted (Actual)
October 12, 2022
Study Record Updates
Last Update Posted (Actual)
February 28, 2024
Last Update Submitted That Met QC Criteria
February 27, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Otorhinolaryngologic Diseases
- Pathological Conditions, Anatomical
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Nose Diseases
- Drug-Related Side Effects and Adverse Reactions
- Drug Hypersensitivity
- Asthma
- Nasal Polyps
- Polyps
- Respiration Disorders
- Respiratory Tract Diseases
- Asthma, Aspirin-Induced
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies, Monoclonal
Other Study ID Numbers
- 2022P002407
- U19AI095219 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nasal Polyps
-
Poitiers University HospitalNot yet recruiting
-
GB001, Inc, a wholly owned subsidiary of Gossamer...CompletedChronic Rhinosinusitis Without Nasal Polyps (CRSsNP) | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)United States, Czechia, Ukraine
-
Ohio State UniversityActive, not recruitingChronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsUnited States
-
Johns Hopkins UniversityGlaxoSmithKlineTerminatedPatients With Nasal Polyps
-
Optinose US Inc.CompletedBilateral Nasal PolyposisUnited States
-
St. Paul's Sinus CentreRecruitingAsthma | Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsCanada
-
Christiane HaaseActive, not recruitingAsthma | Chronic Rhinosinusitis (Diagnosis) | Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsDenmark
-
University Hospital, LilleRecruitingChronic Rhinosinusitis With Nasal PolypsFrance
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingChronic Rhinosinusitis With Nasal PolypsItaly
-
Medical University of South CarolinaRecruitingChronic Rhinosinusitis With Nasal PolypsUnited States
Clinical Trials on Dupilumab
-
Brigham and Women's HospitalRegeneron PharmaceuticalsRecruiting
-
Akron Children's HospitalRegeneron Pharmaceuticals; Ohio State UniversityNot yet recruiting
-
University of MichiganRegeneron PharmaceuticalsRecruiting
-
Northwestern UniversityRecruitingSkin DiseasesUnited States
-
University of California, San FranciscoRecruiting
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAsthma; EosinophilicSpain
-
Montefiore Medical CenterRegeneron PharmaceuticalsRecruitingChronic Rhinosinusitis With Nasal PolypsUnited States
-
Johns Hopkins UniversityDoris Duke Charitable FoundationRecruiting
-
University of RochesterNot yet recruiting